ClinicaliQ Trial Snapshot
- Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE) — Recruiting • Non-phase study • Cardiology / Cardiovascular • NCT03573089.
- What is being tested: A pragmatic randomised controlled trial comparing the effects of high versus standard blood phosphate targets in patients with end-stage kidney disease, to determine whether lowering phosphate levels improves patient-centred clinical outcomes beyond current guideline recommendations.
- Patient eligibility overview: The trial includes patients with end-stage kidney disease (specific eligibility criteria would be detailed in full protocol); participants are randomised to receive treatment targeting either high or standard phosphate levels, with pragmatic design reflecting real-world clinical practice.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
During end-stage kidney disease, clinical guidelines suggest reducing elevated phosphate levels in the blood. However, the effect of lowering blood phosphate levels on important patient-centred outcomes has never been tested. This trial will evaluate whether compared to high levels, lowering blood phosphate levels would reduce death or major events due to heart disease, improve physical health, and be cost-effective.
Eligibility Snapshot
- : 1. Age ≥45 years, or Age ≥18 years with diabetes, 2. ESKD on haemodialysis or peritoneal dialysis, for at least 3 months, 3. Currently prescribed at least one phosphate-lowering medication at any dose 4. Able to provide informed consent
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.